JP2018527912A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018527912A5 JP2018527912A5 JP2018506135A JP2018506135A JP2018527912A5 JP 2018527912 A5 JP2018527912 A5 JP 2018527912A5 JP 2018506135 A JP2018506135 A JP 2018506135A JP 2018506135 A JP2018506135 A JP 2018506135A JP 2018527912 A5 JP2018527912 A5 JP 2018527912A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 114
- 102000036639 antigens Human genes 0.000 claims description 114
- 108091007433 antigens Proteins 0.000 claims description 114
- 239000012634 fragment Substances 0.000 claims description 113
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 61
- 210000004027 cell Anatomy 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 22
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 19
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 10
- 208000035473 Communicable disease Diseases 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 210000000822 natural killer cell Anatomy 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000000018 receptor agonist Substances 0.000 claims 1
- 229940044601 receptor agonist Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 8
- 102000025171 antigen binding proteins Human genes 0.000 description 6
- 108091000831 antigen binding proteins Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201506227V | 2015-08-06 | ||
| SG10201506227V | 2015-08-06 | ||
| PCT/EP2016/068780 WO2017021540A1 (en) | 2015-08-06 | 2016-08-05 | Il2rbeta/common gamma chain antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018527912A JP2018527912A (ja) | 2018-09-27 |
| JP2018527912A5 true JP2018527912A5 (enExample) | 2019-09-19 |
| JP6908591B2 JP6908591B2 (ja) | 2021-07-28 |
Family
ID=56889037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506135A Active JP6908591B2 (ja) | 2015-08-06 | 2016-08-05 | Il2rベータ/共通ガンマ鎖抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10167338B2 (enExample) |
| EP (2) | EP3428193B1 (enExample) |
| JP (1) | JP6908591B2 (enExample) |
| KR (1) | KR102753399B1 (enExample) |
| CN (2) | CN115925939A (enExample) |
| AU (1) | AU2016301970A1 (enExample) |
| CA (1) | CA2994906A1 (enExample) |
| CY (1) | CY1121197T1 (enExample) |
| DK (1) | DK3328894T3 (enExample) |
| ES (2) | ES2710618T3 (enExample) |
| HU (1) | HUE043421T2 (enExample) |
| PL (1) | PL3328894T3 (enExample) |
| PT (1) | PT3328894T (enExample) |
| TR (1) | TR201901445T4 (enExample) |
| TW (1) | TW201713699A (enExample) |
| WO (1) | WO2017021540A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6240063B2 (ja) | 2011-04-28 | 2017-11-29 | ザ ブロード インスティテュート, インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| AU2016301970A1 (en) | 2015-08-06 | 2018-03-22 | Agency For Science, Technology And Research | IL2Rbeta/common gamma chain antibodies |
| EP4099015A1 (en) | 2016-06-10 | 2022-12-07 | Gadeta B.V. | Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response |
| CA3063807A1 (en) | 2017-05-18 | 2018-11-22 | Umc Utrecht Holding B.V. | Compositions and methods for cell targeting therapies |
| CN118373912A (zh) * | 2017-11-10 | 2024-07-23 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| WO2019178518A1 (en) * | 2018-03-16 | 2019-09-19 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
| CA3100349A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| CA3108865A1 (en) | 2018-08-06 | 2020-02-13 | Medikine, Inc. | Il-2 receptor binding compounds |
| CN112888445B (zh) | 2018-08-30 | 2025-06-10 | 免疫生物公司 | 治疗老年化相关病症的方法 |
| CN120535649A (zh) | 2018-08-30 | 2025-08-26 | 免疫生物公司 | 单链嵌合多肽和其用途 |
| NZ772550A (en) | 2018-08-30 | 2025-08-29 | Immunitybio Inc | Multi-chain chimeric polypeptides and uses thereof |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途 |
| WO2020094834A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| WO2020094836A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| WO2020160242A1 (en) | 2019-02-01 | 2020-08-06 | Regeneron Pharmaceuticals, Inc. | Anti-il2 receptor gamma antigen-binding proteins |
| KR20220035394A (ko) | 2019-06-21 | 2022-03-22 | 에이치씨더블유 바이올로직스, 인크. | 다중-사슬 키메라 폴리펩티드 및 이의 용도 |
| AU2020378282B2 (en) | 2019-11-05 | 2023-05-18 | Medikine, Inc. | Dual IL-2R and IL-7R binding compounds |
| JP7427286B2 (ja) | 2019-11-05 | 2024-02-05 | メディカイン、インコーポレイテッド | IL-2RβγC結合化合物 |
| US20230331858A1 (en) * | 2019-12-24 | 2023-10-19 | Neoleukin Therapeutics, Inc. | Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor |
| KR20220139918A (ko) * | 2020-02-03 | 2022-10-17 | 메디카인 인코포레이티드 | IL-7Rαγc 결합 화합물 |
| JP2023512687A (ja) | 2020-02-03 | 2023-03-28 | メディカイン、インコーポレイテッド | IL-7Rα結合化合物 |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| WO2021163298A1 (en) | 2020-02-11 | 2021-08-19 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| AU2021220870A1 (en) | 2020-02-11 | 2022-08-04 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| WO2021161287A2 (en) | 2020-02-16 | 2021-08-19 | Aulos Bioscience, Inc | Engineered anti-il-2 antibodies |
| CN115836087A (zh) | 2020-04-29 | 2023-03-21 | Hcw生物科技公司 | 抗cd26蛋白及其用途 |
| BR102020009679A2 (pt) * | 2020-05-14 | 2021-11-23 | Fundação Universidade Federal Do Abc - Ufabc | Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele |
| KR20230031280A (ko) | 2020-06-01 | 2023-03-07 | 에이치씨더블유 바이올로직스, 인크. | 노화 관련 장애의 치료 방법 |
| US12024545B2 (en) | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2021247003A1 (en) | 2020-06-01 | 2021-12-09 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| WO2022031871A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Compositions and methods related to il27 receptor binding |
| WO2022032040A1 (en) * | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rb/il2rg synthetic cytokines |
| WO2022031929A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il12rb1-binding molecules and methods of use |
| WO2022032022A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10 receptor binding molecules and methods of use |
| US12122839B2 (en) | 2020-08-05 | 2024-10-22 | Synthekine, Inc. | IFNGR binding synthetic cytokines and methods of use |
| CN116322754A (zh) | 2020-08-05 | 2023-06-23 | 辛德凯因股份有限公司 | Il10ra结合分子及使用方法 |
| WO2022031890A1 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Ifngr2 binding molecules and methods of use |
| US12077594B2 (en) | 2020-08-05 | 2024-09-03 | Synthekine, Inc. | IL2RG binding molecules and methods of use |
| WO2022032005A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il10rb binding molecules and methods of use |
| WO2022032006A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il2rb binding molecules and methods of use |
| KR20250127176A (ko) | 2020-08-05 | 2025-08-26 | 신테카인, 인크. | IL27Rα 결합 분자 및 사용 방법 |
| WO2022032023A2 (en) | 2020-08-05 | 2022-02-10 | Synthekine, Inc. | Il23r binding molecules and methods of use |
| US12291572B2 (en) | 2020-08-05 | 2025-05-06 | Synthekine, Inc. | IL12 receptor synthetic cytokines and methods of use |
| MX2023001491A (es) | 2020-08-05 | 2023-03-08 | Synthekine Inc | Moleculas de union a gp130 y metodos de uso. |
| WO2022150791A2 (en) * | 2021-01-11 | 2022-07-14 | Synthekine, Inc. | Compositions and methods related to il2 receptor binding |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| WO2022187710A1 (en) * | 2021-03-05 | 2022-09-09 | Atreca, Inc. | Epha2 antibodies |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗il-2r抗體及使用方法 |
| KR20240049285A (ko) | 2021-08-26 | 2024-04-16 | 쿄와 기린 가부시키가이샤 | Cd116 및 cd131에 결합하는 이중 특이적 항체 |
| CA3232668A1 (en) | 2021-09-17 | 2023-03-23 | Parker Institute For Cancer Immunotherapy | Switch receptors using il-9 signaling domains |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| CA3236138A1 (en) * | 2021-11-02 | 2023-05-11 | Shiyong GONG | Anti-cd122 antibodies, anti-cd132 antibodies, and related bispecific binding proteins |
| WO2023139293A1 (en) | 2022-01-24 | 2023-07-27 | Novimmune Sa | Composition and methods for the selective activation of cytokine signaling pathways |
| KR20240141206A (ko) * | 2022-02-04 | 2024-09-25 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 대용 사이토카인 폴리펩티드 |
| JP2025508939A (ja) | 2022-03-02 | 2025-04-10 | イミュニティーバイオ インコーポレイテッド | 膵臓癌の治療方法 |
| US11999771B2 (en) | 2022-04-07 | 2024-06-04 | Medikine, Inc. | IL-7Rαγc ligand immunoglobulin fusion proteins |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025534413A (ja) * | 2022-09-30 | 2025-10-15 | フォルテ サブシディアリー,インク. | 抗cd122抗体およびその使用 |
| WO2024086754A2 (en) * | 2022-10-19 | 2024-04-25 | Tentarix Biotherapeutics, Inc. | Multi variable domain therapeutic immunoglobulin |
| EP4646225A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| WO2024146955A1 (en) * | 2023-01-06 | 2024-07-11 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| KR20250152067A (ko) * | 2023-02-22 | 2025-10-22 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-il2ra 항체 및 이의 용도 |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4282761B2 (ja) | 1995-01-09 | 2009-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−2r結合ポリペプチド及びそれをコードするdna分子 |
| AU2937597A (en) * | 1996-05-10 | 1997-12-05 | Biogen, Inc. | Common gamma chain blocking agents |
| US20070098685A1 (en) | 2005-01-19 | 2007-05-03 | Brand Stephen J | Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist |
| CA2656700A1 (en) | 2006-07-06 | 2008-01-10 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Compositions and methods for enhancing the efficacy of il-2 mediated immune responses |
| CA2672229A1 (en) * | 2006-12-14 | 2008-06-19 | Actogenix N.V. | Delivery of binding molecules to induce immunomodulation |
| CN102939305B (zh) * | 2010-04-08 | 2016-08-17 | Jn生物科学有限责任公司 | 对cd122的抗体 |
| US20150132322A1 (en) * | 2012-05-07 | 2015-05-14 | Immune Pharmaceuticals Ltd. | Method of generating human monoclonal antibodies |
| US20140044675A1 (en) * | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| AU2014312190A1 (en) * | 2013-08-28 | 2016-02-18 | Bioasis Technologies Inc. | CNS-targeted conjugates of antibodies |
| AU2016301970A1 (en) | 2015-08-06 | 2018-03-22 | Agency For Science, Technology And Research | IL2Rbeta/common gamma chain antibodies |
-
2016
- 2016-08-05 AU AU2016301970A patent/AU2016301970A1/en not_active Abandoned
- 2016-08-05 PL PL16762975T patent/PL3328894T3/pl unknown
- 2016-08-05 US US15/229,336 patent/US10167338B2/en active Active
- 2016-08-05 EP EP18187373.8A patent/EP3428193B1/en active Active
- 2016-08-05 HU HUE16762975A patent/HUE043421T2/hu unknown
- 2016-08-05 CN CN202210993771.XA patent/CN115925939A/zh active Pending
- 2016-08-05 KR KR1020187006234A patent/KR102753399B1/ko active Active
- 2016-08-05 US US15/750,425 patent/US10472421B2/en active Active
- 2016-08-05 ES ES16762975T patent/ES2710618T3/es active Active
- 2016-08-05 CA CA2994906A patent/CA2994906A1/en active Pending
- 2016-08-05 JP JP2018506135A patent/JP6908591B2/ja active Active
- 2016-08-05 WO PCT/EP2016/068780 patent/WO2017021540A1/en not_active Ceased
- 2016-08-05 ES ES18187373T patent/ES2841799T3/es active Active
- 2016-08-05 DK DK16762975.7T patent/DK3328894T3/en active
- 2016-08-05 TR TR2019/01445T patent/TR201901445T4/tr unknown
- 2016-08-05 TW TW105124993A patent/TW201713699A/zh unknown
- 2016-08-05 PT PT16762975T patent/PT3328894T/pt unknown
- 2016-08-05 CN CN201680046297.2A patent/CN107922496B/zh active Active
- 2016-08-05 EP EP16762975.7A patent/EP3328894B1/en active Active
-
2018
- 2018-02-28 US US15/908,218 patent/US10472423B2/en active Active
- 2018-03-16 US US15/922,921 patent/US10246512B2/en active Active
- 2018-08-24 US US16/112,008 patent/US10696747B2/en active Active
-
2019
- 2019-01-29 CY CY20191100118T patent/CY1121197T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018527912A5 (enExample) | ||
| JP6707496B2 (ja) | Aprilバリアント | |
| JP2018508475A5 (enExample) | ||
| RU2715628C2 (ru) | Антитела к pd-1 | |
| JP6666905B2 (ja) | Pd−l1抗体及びその使用 | |
| JP2018500924A5 (enExample) | ||
| JP2019519208A5 (enExample) | ||
| JP2018138058A (ja) | 間葉及び上皮間葉形質転換循環腫瘍細胞のための特異的検出ツール | |
| JP2020522261A5 (enExample) | ||
| JP2022169504A5 (enExample) | ||
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| JP2018503600A5 (enExample) | ||
| JP2017536111A5 (enExample) | ||
| JP6868655B2 (ja) | Cd6結合パートナーの使用およびそれに基づく方法 | |
| JP2017532005A5 (enExample) | ||
| JP2021500916A5 (enExample) | ||
| JP2022527941A (ja) | 光免疫療法のための方法および関連バイオマーカー | |
| CN115103633B (zh) | 使用多种成像剂的成像方法 | |
| CN103827144A (zh) | 新的抗cxcr4抗体及其用于检测和诊断癌症的用途 | |
| EP2523687A1 (en) | Methods for diagnosis and treatment of cutaneous t cell lymphomas | |
| JP2023519304A (ja) | 多発性骨髄腫における免疫療法の標的およびその同定方法 | |
| JP2014515600A5 (enExample) | ||
| TW201811828A (zh) | 抗原結合分子和使用彼之方法 | |
| CN110809628A (zh) | 使用外周血t细胞的肿瘤细胞毒性活性作为指标预测肿瘤免疫疗法效果的方法 | |
| CN102395602B (zh) | 在疾病治疗方法中使用的b‑淋巴细胞靶向剂 |